Mumbai, February 28, 2024 – The Tata Institute in Mumbai has announced a breakthrough in cancer treatment with the development of a tablet that could prevent cancer recurrence and reduce treatment side effects by 50%.
After a decade of research, the institute’s scientists have created the ‘R+Cu’ tablet containing pro-oxidant compounds with resveratrol and copper. This tablet generates oxygen radicals in the stomach, which destroy chromatin particles released by dying cancer cells, preventing them from turning healthy cells cancerous. The tablet also inhibits the spread of cancer cells in the body.
Dr. Rajendra Badve, a senior cancer surgeon at Tata Memorial Hospital, revealed that initial tests on rodents have shown promising results. Human trials are pending, which could take up to five years. The tablet awaits approval from the Food Safety and Standards Authority of India (FSSAI) and is expected to be available in the market by June-July.
A key highlight of this discovery is its affordability, with the tablet priced at just ₹100, making it accessible to a wider population.
Dr. Badve emphasized the significance of the tablet, stating, “This tablet has the potential to revolutionize cancer treatment. It offers hope to patients and could significantly improve treatment outcomes.”
The ‘R+Cu’ tablet holds promise not only in preventing cancer recurrence but also in reducing treatment side effects. Researchers believe it could be effective in treating various types of cancer, including pancreatic, lung, and oral cancers.
The unveiling of this tablet marks a significant milestone in cancer treatment, offering hope to millions of patients worldwide. With its affordability and effectiveness, the ‘R+Cu’ tablet has the potential to transform the landscape of oncological care.
